Revenue growth confirms Attruby's commercial trajectory, but the EPS miss may pressure the stock near-term. Key catalysts are the BBP-418 PDUFA in November 2026, encaleret PDUFA in May 2027, and upcoming data at ESC 2026. Monitor Attruby market share gains and the impact of the $1B financing on launch execution.
Price Chart
Executive Summary
BridgeBio reported Q2 2026 total revenues of $243.7M (+120.5% YoY), driven by $222.4M in Attruby net product revenue (+211% YoY), but GAAP EPS of $(0.78) missed consensus of $(0.64) by 22%. The company is investing heavily in three upcoming launches and closed a $1B preferred equity financing post-quarter, strengthening its balance sheet for pipeline expansion.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues $243.7M, up 120.5% YoY from $110.6M
- Attruby net product revenue $222.4M, up 211% YoY from $71.5M
- GAAP net loss per share $(0.78) vs consensus $(0.64) — 21.9% miss
- Three NDAs under FDA Priority Review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 8, 2027), infigratinib (submitted)
- $1B preferred equity financing closed July 1, 2026, led by Sixth Street
- Cash, equivalents, and marketable securities $720.2M as of June 30, 2026
- Operating expenses surged to $350.8M (+43.3% YoY) as company scales for three launches
Financial Impact
Revenue growth offset by 22% EPS miss and 43% operating expense increase; net loss improved to $152.2M from $181.9M YoY
Risk Factors
- EPS miss of 22% vs consensus raises concerns about expense trajectory
- R&D and SG&A spending growing faster than revenue, delaying profitability
- Dependence on Attruby for near-term revenue; pipeline approvals are binary events
- High debt load with $2.5B in notes and deferred royalty obligations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342182 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access